Novartis Preferred Stock for Neurovance
In spring 2012, Edwards Wildman Venture Capital lawyers in Boston represented Novartis Bioventures in the third and fourth closing of Series A Preferred Stock financings for Neurovance, Inc. Novartis is a Cambridge, Massachusetts-based venture fund. Neurovance, Inc., also based in Cambridge, Massachusetts, focuses on developing pharmaceutical preparations for the treatment of disorder of the central nervous system. The company was founded in 2011. Novartis Bioventures, is a life science focused venture fund based in Cambridge, Massachusetts.
Posted on May 21, 2012
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.